Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586662 | 0.84 | ALDH1A1 (0.47) | LMNACYP1A2ALDH1A1ALOX15TSHR | |
| SCHEMBL218726 | 0.77 | ALDH1A1 (0.54) | CYP1A2ALDH1A1ALOX15TSHR | |
| SCHEMBL801870 | 0.77 | ALDH1A1 (0.39) | CYP1A2ALDH1A1ALOX15TSHRMEN1 | |
| SCHEMBL10376639 | 0.77 | LMNA (0.50) | LMNAIDO1 | |
| SCHEMBL8733589 | 0.74 | ALDH1A1 (0.61) | CYP1A2ALDH1A1ALOX15TSHR | |
| SCHEMBL7157400 | 0.73 | LMNA (0.41) | LMNATSHRKDM4EIDO1MEN1 | |
| SCHEMBL20421684 | 0.72 | TLR8 (0.44) | LMNACYP1A2ALDH1A1KDM4EIDO1 | |
| SCHEMBL3847571 | 0.72 | ALDH1A1 (0.35) | LMNAALDH1A1ALOX15TSHRKDM4E | |
| SCHEMBL10043017 | 0.72 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR | |
| SCHEMBL16247844 | 0.72 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0004945-B1 | PROCESS FOR THE PREPARATION OF 2.4-DIFLUORO-5-CHLORO-6-METHYLPYRIMIDINE | BAYER AG (DE) | 1982-03-03 | — | — | EP | claimed |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| CN-120192324-A | Heterocyclic compound, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4534534-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119707948-A | Spiro heterocycle substituted pyrimidine compound and preparation method and application thereof | 上海美悦生物科技发展有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119585256-A | Chemokine receptor modulators and uses thereof | 拉普特医疗公司 | 2025-03-07 | — | — | CN | disclosed |
| US-12240837-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-0004945-A1 | Process for the preparation of 2.4-Difluoro-5-chloro-6-methylpyrimidine | BAYER AG (DE) | 1979-10-31 | — | — | EP | disclosed |
| US-4141890-A | FIBER-REACTIVE | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-RE29585-E | DYEING WOOL | CIBA-GEIGY CORPORATION (US) | 1978-03-21 | — | — | US | disclosed |
| US-4067864-A | FOR CELLULOSE OR POLYAMIDES | CIBA-GEIGY AG (CH) | 1978-01-10 | — | — | US | disclosed |
| US-4039523-A | YELLOW | CIBA-GEIGY AG (CH) | 1977-08-02 | — | — | US | disclosed |
| US-4017477-A | 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs | CIBA-GEIGY AG (CH) | 1977-04-12 | — | — | US | disclosed |
| US-4001205-A | WATER-SOLUBLE, FIBER-REACTIVE PHENYLAZODIHYDROXY, METHYL, CYANOPYRIDINE DYESTUFFS | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-4001203-A | Heavy metal complexes of azo dyestuffs containing a heterocyclic diazo component and the residue of 5-halogeno-2,3-dihydrozypyridine as coupling component | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-3971738-A | Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
| US-3956263-A | 4-Methyl-2,6-dihydroxy-3-cyanopyridine containing dyestuffs | CIBA-GEIGY AG (CH) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR1, CXCR2, CCR2 | LMNA 3574/4885CYP1A2 3337/4885ALDH1A1 3882/4885 |
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | CCR4, CCR1, CCR3 | LMNA 4301/4885CYP1A2 1463/4885ALDH1A1 1894/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | LMNA 1096/4885CYP1A2 2422/4885ALDH1A1 1171/4885 |
| US-12240837-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | LMNA 4823/4885CYP1A2 4297/4885ALDH1A1 2077/4885 |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | OGFR, CBR3, CBR1 | LMNA 3941/4885CYP1A2 305/4885ALDH1A1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.